HC Wainwright Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $22.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective lowered by equities researchers at HC Wainwright from $25.00 to $22.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 106.57% from the company’s previous close.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. upped their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. Finally, TD Cowen began coverage on shares of Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating and a $34.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $26.14.

Day One Biopharmaceuticals Stock Down 2.6%

DAWN stock opened at $10.65 on Wednesday. Day One Biopharmaceuticals has a twelve month low of $5.64 and a twelve month high of $13.20. The company has a market cap of $1.10 billion, a PE ratio of -10.34 and a beta of -1.26. The business’s 50-day simple moving average is $10.69 and its 200 day simple moving average is $8.77.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. The firm had revenue of $53.72 million during the quarter, compared to analyst estimates of $49.81 million. On average, equities research analysts anticipate that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Insider Activity

In other news, CFO Charles N. York II sold 6,065 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the completion of the sale, the chief financial officer owned 312,025 shares of the company’s stock, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jeremy Bender sold 15,459 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $179,324.40. Following the completion of the transaction, the chief executive officer owned 204,603 shares of the company’s stock, valued at $2,373,394.80. This trade represents a 7.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,461 shares of company stock worth $422,948 over the last ninety days. Corporate insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its position in Day One Biopharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after purchasing an additional 1,029 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Day One Biopharmaceuticals by 1.4% in the fourth quarter. Los Angeles Capital Management LLC now owns 100,314 shares of the company’s stock valued at $935,000 after buying an additional 1,425 shares in the last quarter. Perkins Capital Management Inc. raised its holdings in shares of Day One Biopharmaceuticals by 2.1% in the fourth quarter. Perkins Capital Management Inc. now owns 84,000 shares of the company’s stock valued at $783,000 after buying an additional 1,750 shares during the last quarter. CWM LLC raised its holdings in shares of Day One Biopharmaceuticals by 32.4% in the fourth quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after buying an additional 2,051 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in Day One Biopharmaceuticals by 12.9% during the 2nd quarter. ProShare Advisors LLC now owns 18,545 shares of the company’s stock worth $121,000 after buying an additional 2,121 shares in the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Wedbush raised its price target to $30 and kept an “outperform” rating, signaling strong upside potential from current levels and offering a bullish institutional endorsement. Wedbush PT Raise
• Positive Sentiment: Revenue beat — Q4 revenue came in above consensus (company reported ~$53.7M vs est. ~$49.8M), described as record revenue growth, which supports top‑line momentum and future commercial prospects. Earnings Highlights
• Neutral Sentiment: Analyst roundup pieces summarizing multiple firms’ views are circulating, providing varied takes that can sustain volatility as investors parse differing price targets and ratings. Analyst Roundup
• Neutral Sentiment: Short-interest report shows 0 shares noted for the period (data appears anomalous), so current short-interest metrics provide no clear signal and should be treated cautiously.
• Neutral Sentiment: Earnings materials and full transcripts are available for deeper review (presentation and call transcripts), useful for investors who want management commentary on guidance, commercial rollout and cost trajectory. Earnings Presentation
• Negative Sentiment: EPS missed expectations — Q4 GAAP loss was $0.21 per share vs. the consensus loss of $0.17, highlighting ongoing profitability pressure and contributing to near-term downside risk. EPS Miss Coverage
• Negative Sentiment: Some analysts trimmed price targets (Needham cut to $17; HC Wainwright lowered to $22) even while keeping “buy” ratings — these reductions reduce consensus upside and can weigh on sentiment despite revenue strength. Analyst PT Changes

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.